12 February 2026 ORYZON announces appointment of Rolando Gutierrez-Esteinou, M.D., as Chief Medical Officer for CNS
9 February 2026 ORYZON announces first patient dosed in an Investigator-initiated Phase Ib study of iadademstat in extensive stage small cell lung cancer
2 February 2026 ORYZON strengthens patent portfolio for vafidemstat with new Decision to Grant in Japan
11 January 2026 9th Sachs Annual Neuroscience Innovation Forum Marines’ Memorial Club, San Francisco CA United States
22 December 2025 ORYZON expands global patent protection for iadademstat with grant decision in Japan covering combinations with PD-1/PD-L1 inhibitors
15 December 2025 ORYZON announces the voting results of December 2025 Extraordinary General Shareholders' Meeting